Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases

JAMA Internal Medicine(2022)10.1001/jamainternmed.2022.0338Source: DataRank Database

Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases is a research paper published in JAMA Internal Medicine (2022). On theSindex it has a DataRank of 0.862. It has been cited 312 times.

N/A

0.862DataRank · unranked

Scored on demand from live citation data

312 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Impact (FWCI 29.60)OA: bronzeTopics (29)Linked Datasets (12)DataCite Reuse (12)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (0/2)

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.862

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (9)

Jialu Wang ORCID,Fan Ping ORCID,Na Yang ORCID,Jingyue Huang,Yuxiu Li ORCID

Live enrichment

PubMed:35344001 OpenAlex:https://openalex.org/W4220972902

FWCI

29.60

Citation Percentile

1.0%

Influential Citations

Citation Trend

2022

2023

2024

2025

2026

bronze

journalhttps://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2790392/jamainternal_he_2022_oi_220009_1650900276.01193.pdf

BRONZEhttps://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2790392/jamainternal_he_2022_oi_220009_1650900276.01193.pdf

publisherhttps://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2790392/jamainternal_he_2022_oi_220009_1650900276.01193.pdf

journalhttps://doi.org/10.1001/jamainternmed.2022.0338

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35344001

Fields of Study

Diabetes Treatment and ManagementGallbladder and Bile Duct DisordersBariatric Surgery and OutcomesMedicine

MeSH Terms

Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsAdultCholecystitisCholelithiasisDiabetes Mellitus, Type 2FemaleHumansMaleMiddle AgedWeight LossRandomized Controlled Trials as TopicGlucagon-Like Peptide 1

Keywords

MedicineCochrane LibraryInternal medicineRandomized controlled trialMEDLINEGallbladderClinical trialMeta-analysisPlaceboGastroenterologyPathologyAlternative medicine

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials

10.6084/m9.figshare.21383024.v1figshare

Additional file 1 of Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials

10.6084/m9.figshare.21383024figshare

Additional file 3 of Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials

10.6084/m9.figshare.21383030figshare

Additional file 3 of Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials

10.6084/m9.figshare.21383030.v1figshare

Additional file 4 of Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials

10.6084/m9.figshare.21383033.v1figshare

Additional file 4 of Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials

10.6084/m9.figshare.21383033figshare

Additional file 5 of Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials

10.6084/m9.figshare.21383036.v1figshare

Additional file 5 of Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials

10.6084/m9.figshare.21383036figshare

Additional file 1 of Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database

10.6084/m9.figshare.26680684.v1figshare

10.6084/m9.figshare.26680684figshare

Additional file 2 of Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials

10.6084/m9.figshare.21383027figshare

Additional file 2 of Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials

10.6084/m9.figshare.21383027.v1figshare